Abstract
Introduction
Long-acting muscarinic antagonists (LAMA) or beta-2 agonists (LABA) have been recommended for symptom control in group A COPD patients as a first-line bronchodilator treatment in GOLD guidelines. However, there is no mention of priority/superiority between the two treatment options. We aimed to compare the effectiveness of these treatments in this group.
Methods
The study cohort was formed of all subjects from six pulmonology clinics with an initial diagnosis of COPD who were new users of a LAMA or LABA from January 2020 to December 2021. Seventy-six group A COPD patients, in whom LABA or LAMA therapy had been started in the last 1 month as a first-line treatment, were included in our study. Participants were evaluated with spirometry, COPD Assessment Test (CAT), mMRC scale, and St. George Respiratory Questionnaire (SGRQ) for three times (baseline, 6–12th months).
Results
There were 76 group A COPD patients with LAMA (67.1%) and LABA (32.9%). The number of patients who improved in CAT score at the end of the first year was significantly higher in patients using LAMA than those using LABA (p = 0.022); the improvement at minimum clinically important difference (MCID) in CAT score of LAMA group at 1st year was also significant (p = 0.044). SGRQ total and impact scores were found to be statistically lower at 1st year compared to baseline in patients using LAMA (p = 0.010 and 0.006, respectively). Significant improvement was detected in CAT and SGRQ scores at the 6th month visit in the LAMA group having emphysema (p = 0.032 and 0.002, respectively).
Conclusion
According to significant improvements in CAT and SGRQ score, LAMA may be preferred over LABA as a bronchodilator agent in group A COPD patients, especially in emphysema-dominant phenotype.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author, [Onur Turan], upon reasonable request.
References
Initiative for chronic obstructive lung disease--GOLD (2016) Global Strategy for the diagnosis, management and prevention of COPD. Bethesda: Global ınitiative for chronic obstructive lung disease. https://www.goldcopd.org
Initiative for chronic obstructive lung disease--GOLD (2021) Global Strategy for the diagnosis, management and prevention of COPD. Bethesda: Global ınitiative for chronic obstructive lung disease. https://www.goldcopd.org
Appleton S, Poole P, Smith B et al (2006) Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 19:CD001104
Oishi K, Hirano T, Hamada K et al (2018) Characteristics of 2017 GOLD COPD group A: a multicenter cross-sectional CAP study in Japan. Int J Chron Obstruct Pulmon Dis 5(13):3901–3907. https://doi.org/10.2147/COPD.S181938. PMID: 30584291; PMCID: PMC6287652
Bestall JC, Paul EA, Garrod R et al (1999) Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54:581–586. https://doi.org/10.1136/thx.54.7.581
Jones PW, Harding G, Berry P et al (2009) Development and first validation of the COPD assessment test. Eur Respir J 34:648–654. https://doi.org/10.1183/09031936.00102509
Jones PW, Quirk FH, Baveystock CM et al (1992) A self-complete measure of health status for chronic airflow limitation. The St. George’s respiratory questionnaire. Am Rev Respir Dis 145:1321–1327
Mahler DA, Wells CK (1988) Evaluation of clinical methods for rating dyspnea. Chest J 93(3):580–586. https://doi.org/10.1378/chest.93.3.580
Polatlı M, Yorgancıoğlu A, Aydemir Ö et al (2013) Validity and reliability of Turkish version of St. George’s respiratory questionnaire Tuberk Toraks 61:81–87
Tsiligianni IG, Alma HJ, de Jong C et al (2016) Investigating sensitivity, specificity, and area under the curve of the Clinical COPD Questionnaire, COPD Assessment Test, and Modified Medical Research Council scale according to GOLD using St George’s Respiratory Questionnaire cutoff 25 (and 20) as reference. Int J Chron Obstruct Pulmon Dis 18(11):1045–1052
Safka KA, Wald J, Wang H et al (2017) GOLD stage and treatment in COPD: a 500 patient point prevalence study. Chronic Obstr Pulm Dis 4(1):45–55. https://doi.org/10.15326/jcopdf.4.1.2016.0126
Chhabra SK, Vijayan VK, Vasu T (2006) Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 48(2):97–102
Kim JS, Park J, Lim SY et al (2015) Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trials. PLoS One 23;10(3):e0119948. https://doi.org/10.1371/journal.pone.0119948
Decramer ML, Chapman KR, Dahl R et al (2013) Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 1:524–533
Koarai A, Sugiura H, Yamada M et al (2020) Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. BMC Pulm Med 20(1):111. https://doi.org/10.1186/s12890-020-1152-8
Jones PW, Brusselle G, Dal Negro RW et al (2011) Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J 38(1):29–35
Fujimoto K, Kitaguchi Y, Kanda S et al (2011) Comparison of efficacy of long-acting bronchodilators in emphysema dominant and emphysema nondominant chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 6:219–227. https://doi.org/10.2147/COPD.S18461. Epub 2011 Apr 1
Tomioka H, Sekiya R, Nishio C et al (2014) Impact of smoking cessation therapy on health-related quality of life. BMJ Open Respir Res 1(1):e000047. Published Aug 28 2014. https://doi.org/10.1136/bmjresp-2014-000047
Tillmann M, Silcock J (1997) A comparison of smokers’ and ex-smokers’ health-related quality of life. J Public Health Med 19(3):268–273
Mahler DA, Kerstjens HA, Donohue JF et al (2015) Indacaterol vs tiotropium in COPD patients classified as GOLD A and B. Respir Med 109(8):1031–1039. https://doi.org/10.1016/j.rmed.2015.05.012. Epub 2015 May 22
Author information
Authors and Affiliations
Contributions
Onur Turan wrote the main manuscript text and prepared figures and tables. Nalan Ogan, Fulsen Bozkus, Nurhan Sarıoğlu, Pakize Ayşe Turan and Celal Satıcı had contribution to data collection.
Corresponding author
Ethics declarations
Consent for publication
All authors have approval about this manuscript.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Onur Turan, Nalan Ogan, Fulsen Bozkus, Nurhan Sarıoğlu, Pakize Ayşe Turan, and Celal Satıcı have no relationships within the industry for 2 years.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Turan, O., Ogan, N., Bozkus, F. et al. Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients?. Eur J Clin Pharmacol (2024). https://doi.org/10.1007/s00228-024-03637-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00228-024-03637-1